Characterization of polymyxin B biodistribution and disposition in an animal model

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 2, 2016, Pages 1029-1034

  Manchandani, Pooja ^a   Zhou, Jian ^a   Ledesma, Kimberly R ^a   Truong, Luan D ^b   Chow, Diana S L ^a   Eriksen, Jason L ^a   Tam, Vincent H ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POLYMYXIN B; ANTIINFECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILIARY EXCRETION; CELLS BY BODY ANATOMY; CONTROLLED STUDY; DRUG BILE LEVEL; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; DRUG UPTAKE; DRUG URINE LEVEL; FEMALE; IMMUNOHISTOCHEMISTRY; KIDNEY TUBULE CELL; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; BLOOD; DRUG EFFECTS; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; METABOLISM; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION;

ANIMALS; ANTI-BACTERIAL AGENTS; FEMALE; INJECTIONS, INTRAVENOUS; KIDNEY; POLYMYXIN B; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 84957927076     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02445-15     Document Type: Article

References (28)

1. Vergidis PI, Falagas ME. 2008. Multidrug-resistant Gram-negative bacterial infections: the emerging threat and potential novel treatment options. Curr Opin Investig Drugs 9:176-183.
2. Curcio D. 2014. Multidrug-resistant Gram-negative bacterial infections: are you ready for the challenge? Curr Clin Pharmacol 9:27-38. http://dx.doi.org/10.2174/15748847113089990062.
3. de Bentzmann S, Plesiat P. 2011. The Pseudomonas aeruginosa opportunistic pathogen and human infections. Environ Microbiol 13:1655-1665. http://dx.doi.org/10.1111/j.1462-2920.2011.02469.x.
4. Kielhofner M, Atmar RL, Hamill RJ, Musher DM. 1992. Life-threatening Pseudomonas aeruginosa infections in patients with human immunodeficiency virus infection. Clin Infect Dis 14:403-411. http://dx.doi.org/10.1093/clinids/14.2.403.
5. Decre D, Verdet C, Emirian A, Le Gourrierec T, Petit JC, Offenstadt G, Maury E, Brisse S, Arlet G. 2011. Emerging severe and fatal infections due to Klebsiella pneumoniae in two university hospitals in France. J Clin Microbiol 49:3012-3014. http://dx.doi.org/10.1128/JCM.00676-11.
6. Montefour K, Frieden J, Hurst S, Helmich C, Headley D, Martin M, Boyle DA. 2008. Acinetobacter baumannii: an emerging multidrug-resistant pathogen in critical care. Crit Care Nurse 28:15-26.
7. Baijal R, Amarapurkar D, Praveen Kumar HR, Kulkarni S, Shah N, Doshi S, Gupta D, Jain M, Patel N, Kamani P, Issar SK, Dharod M, Shah A, Chandnani M, Gautam S. 2014. A multicenter prospective study of infections related morbidity and mortality in cirrhosis of liver. Indian J Gastroenterol 33:336-342. http://dx.doi.org/10.1007/s12664-014-0461-3.
8. Tumbarello M, Trecarichi EM, De Rosa FG, Giannella M, Giacobbe DR, Bassetti M, Losito AR, Bartoletti M, Del Bono V, Corcione S, Maiuro G, Tedeschi S, Celani L, Cardellino CS, Spanu T, Marchese A, Ambretti S, Cauda R, Viscoli C, Viale P, Isgri S. 2015. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother 70:2133-2143.
9. Kvitko CH, Rigatto MH, Moro AL, Zavascki AP. 2011. Polymyxin B versus other antimicrobials for the treatment of pseudomonas aeruginosa bacteraemia. J Antimicrob Chemother 66:175-179. http://dx.doi.org/10.1093/jac/dkq390.
10. Fernandez L, Gooderham WJ, Bains M, McPhee JB, Wiegand I, Hancock RE. 2010. Adaptive resistance to the "last hope" antibiotics polymyxin B and colistin in Pseudomonas aeruginosa is mediated by the novel two-component regulatory system ParR-ParS. Antimicrob Agents Chemother 54:3372-3382. http://dx.doi.org/10.1128/AAC.00242-10.
11. Zavascki AP, Goldani LZ, Li J, Nation RL. 2007. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother 60:1206-1215. http://dx.doi.org/10.1093/jac/dkm357.
12. Zavascki AP, Li J, Nation RL, Superti SV, Barth AL, Lutz L, Ramos F, Boniatti MM, Goldani LZ. 2009. Stable polymyxin B susceptibility to Pseudomonas aeruginosa and Acinetobacter spp. despite persistent recovery of these organisms from respiratory secretions of patients with ventilator-associated pneumonia treated with this drug. J Clin Microbiol 47:3064-3065. http://dx.doi.org/10.1128/JCM.01035-09.
13. Yuan Z, Tam VH. 2008. Polymyxin B: a new strategy for multidrug-resistant Gram-negative organisms. Expert Opin Investig Drugs 17:661-668. http://dx.doi.org/10.1517/13543784.17.5.661.
14. Shoji J, Hinoo H, Wakisaka Y, Koizumi K, Mayama M, Matsuura S. 1977. Isolation of two new polymyxin group antibiotics. (Studies on antibiotics from the genus Bacillus. XX.) J Antibiot 30:1029-1034. http://dx.doi.org/10.7164/antibiotics.30.1029.
15. Orwa JA, Govaerts C, Busson R, Roets E, Van Schepdael A, Hoogmartens J. 2001. Isolation and structural characterization of polymyxin B components. J Chromatogr A 912:369-373. http://dx.doi.org/10.1016/S0021-9673(01)00585-4.
16. He J, Ledesma KR, Lam WY, Figueroa DA, Lim TP, Chow DS, Tam VH. 2010. Variability of polymyxin B major components in commercial formulations. Int J Antimicrob Agents 35:308-310. http://dx.doi.org/10.1016/j.ijantimicag.2009.11.005.
17. Manchandani P, Eriksen JL, Tam VH. 2014. Abstr 54th Intersci Conf Antimicrob Agents Chemother, abstr A-030.
18. Manchandani P, Ledesma KR, Zhou J, Tam VH. 2015. Abstr 55th Intersci Conf Antimicrob Agents Chemother, abstr A-930.
19. He J, Gao S, Hu M, Chow DS, Tam VH. 2013. A validated ultra-performance liquid chromatography-tandem mass spectrometry method for the quantification of polymyxin B in mouse serum and epithelial lining fluid: application to pharmacokinetic studies. J Antimicrob Chemother 68:1104-1110. http://dx.doi.org/10.1093/jac/dks536.
20. He J, Figueroa DA, Lim TP, Chow DS, Tam VH. 2010. Stability of polymyxin B sulfate diluted in 0.9% sodium chloride injection and stored at 4 or 25 degrees C. Am J Health Syst Pharm 67:1191-1194. http://dx.doi.org/10.2146/ajhp090472.
21. Kunin CM, Bugg A. 1971. Binding of polymyxin antibiotics to tissues: the major determinant of distribution and persistence in the body. J Infect Dis 124:394-400. http://dx.doi.org/10.1093/infdis/124.4.394.
22. Kunin CM, Bugg A. 1971. Recovery of tissue bound polymyxin B and colistimethate. Proc Soc Exp Biol Med 137:786-790. http://dx.doi.org/10.3181/00379727-137-35667.
23. Abdelraouf K, He J, Ledesma KR, Hu M, Tam VH. 2012. Pharmacokinetics and renal disposition of polymyxin B in an animal model. Antimicrob Agents Chemother 56:5724-5727. http://dx.doi.org/10.1128/AAC.01333-12.
24. Yun B, Azad MA, Wang J, Nation RL, Thompson PE, Roberts KD, Velkov T, Li J. 2015. Imaging the distribution of polymyxins in the kidney. J Antimicrob Chemother 70:827-829. http://dx.doi.org/10.1093/jac/dku441.
25. Abdelraouf K, Braggs KH, Yin T, Truong LD, Hu M, Tam VH. 2012. Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design. Antimicrob Agents Chemother 56:4625-4629. http://dx.doi.org/10.1128/AAC.00280-12.
26. Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, Behle TF, Bordinhao RC, Wang J, Forrest A, Nation RL, Li J, Zavascki AP. 2013. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 57:524-531. http://dx.doi.org/10.1093/cid/cit334.
27. Zavascki AP, Goldani LZ, Cao G, Superti SV, Lutz L, Barth AL, Ramos F, Boniatti MM, Nation RL, Li J. 2008. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis 47:1298-1304. http://dx.doi.org/10.1086/592577.
28. Falagas ME, Bliziotis IA, Tam VH. 2007. Intraventricular or intrathecal use of polymyxins in patients with Gram-negative meningitis: a systematic review of the available evidence. Int J Antimicrob Agents 29:9-25. http://dx.doi.org/10.1016/j.ijantimicag.2006.08.024.